DUBLIN/ATHLONE, IRELAND – Danish pharmaceutical giant Novo Nordisk, the company behind the blockbuster diabetes and weight-loss drugs Ozempic and Wegovy, is proceeding with significant job cuts at its Irish facility in Athlone. The move is part of a major company-wide global transformation aimed at streamlining operations and sharpening its focus on core growth areas.
Irish Operations Impact
The company has notified the Department of Enterprise of a collective redundancy, a process legally required for any plan involving 30 or more layoffs. Local reports indicate that the Novo Nordisk facility in Monksland, Athlone, is planning to make approximately 75 workers mandatorily redundant.
This figure is in addition to the approximately 40 voluntary redundancies that were recently announced at the Athlone site. Cumulatively, the job losses in the Irish operation are expected to total around 115 positions. The Athlone facility is a key part of the company’s global network, though the full extent of the departmental cuts has not been disclosed.
Global Strategy for ‘Agility’
A spokesperson for Novo Nordisk confirmed that the Irish job cuts are aligned with the company’s recently announced plan to reduce its global workforce by approximately 9,000 positions out of its total of 78,400 employees, representing an over 11% reduction worldwide.
The company’s new President and CEO, Mike Doustdar, stated that the transformation is necessary to “simplify our organisation, improve the speed of decision-making, and reallocate resources” to the company’s leading therapy areas: diabetes and obesity. The pharmaceutical market, particularly for weight-loss treatments, has become “more competitive and consumer-driven,” necessitating a shift in the company’s approach.
The restructuring, which is expected to result in total annualised savings of approximately DKK 8 billion (about $1.25 billion) by the end of 2026, will see those savings redirected into core areas, including commercial execution, R&D programs, and manufacturing scale-up for its popular drugs.
Novo Nordisk confirmed that the implementation of the global workforce reduction will begin immediately, with communication to affected employees occurring over the next few months, subject to local labour market requirements.
